1］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132. ［2］Wang B，Liu SZ，Zheng RS，et al.Time trends of ovarian cancer incidence in China［J］.Asian Pacific Journal of Cancer Prevention，2014，15(1)：191-193. ［3］Lee JY，Kim EY，Jung KW，et al.Trends in gynecologic cancer mortality in East Asian regions［J］.Gynecol Oncol，2014，25(3)：174-182. ［4］Wu QJ，Vogtmann E，Zhang W，et al.Cancer incidence among adolescents and young adults in urban Shanghai，1973-2005［J］.PLoS One，2012，7(8)：520-521. ［5］Kim K，Zang R，Choi SC，et al.Current status of gynecological cancer in China［J］.Journal of Gynecologic Oncology，2009，20(2)：72-76. ［6］Jemal A，Bray F，Center MM，et al.Global cancer statistics，2012［J］.CA Cancer J Clin，2011，61(2)：69-90. ［7］Reed N，Millan D，Verheijen R，et al.Non-epithelial ovarian cancer： ESMO clinical practice guidelines for diagnosis，treatment and follow-up［J］.Annals of Oncology，2010，20 Suppl 4(suppl_5)：24-26. ［8］Argento M，Hoffman P，Gauchez AS.Ovarian cancer detection and treatment： Current situation and future prospects［J］.Anticancer Research，2008，28(5B)：3135-3138. ［9］Ozols RF，Bookman MA，Connolly DC，et al.Focus on epithelial ovarian cancer［J］.Cancer Cell，2004，5(1)：19-24. ［10］Colombo N，Van GT，Parma G，et al.Ovarian cancer［J］.Critical Reviews in Oncology/Hematology，2006，60(2)：159-179. ［11］Roupa Z，Faros E，Raftopoulos V，et al.Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening［J］.Vivo，2004，18(6)：831-836. ［12］Zhang Yan，Li Yali.Research progress in tumor markers for the early diagnosis of ovarian cancer［J］.Journal of International Obstetrics and Gynecology，2012，39(2)：148-151.［张彦，李亚里.肿瘤标记物用于卵巢癌早期诊断的研究进展［J］.国际妇产科学杂志，2012，39(2)：148-151］ ［13］Yang ZJ，Zhao BB，Li L.The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer［J］.Journal of Ovarian Research，2016，9(1)：57. ［14］Dayyani F，Uhlig S，Colson B，et al.Diagnostic performance of risk of ovarian malignancy algorithm against ca125 and he4 in connection with ovarian cancer： A meta-analysis［J］.International Journal of Gynecological Cancer，2016，26(9)： 1586-1593. ［15］Zhang P，Wang C，Cheng L，et al.Comparison of HE4，CA125，and ROMA diagnostic accuracy： A prospective and multicenter study for chinese women with epithelial ovarian cancer［J］.Medicine，2015，94(52)：e2402. ［16］Kirchhoff C，Habben I，Ivell R，et al.A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors［J］.Biology of Reproduction，1991，45(2)：350-357. ［17］Bingle L，Singleton V，Bingle CD.The putative ovarian tumour marker gene HE4 (WFDC2)，is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms［J］.Oncogene，2002，21(17)：2768-2773. ［18］Jia MM，Deng J，Cheng XL.Diagnosticaccuracy of urine HE4 in patients with ovariancancer： A meta-analysis［J］.Oncogene，2017，8(6)：9660-9671. ［19］Smith JB，Stashwick C，Powell DJ .B7-H4 as a potential target for immunotherapy for gynecologic cancers： A closer look［J］.Gynecol Oncol，2014，134(1)：181-189. ［20］Simon I，Zhuo S，Corral L.B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer［J］.Cancer Res，2006，66(3)：1570-1575. ［21］Pua TL，Wang FQ，Fishman DA.Roles of LPA in ovarian cancer development and progression［J］.Future Oncol，2009，5(10)：1659-1673. ［22］Yuan Qi，Zheng Shumin.The values of serum hysophosphatidic acid and human epididymis protein 4 and CA125 assay in the diagnosis of ovarian carcinoma［J］.National Medical Frontiers of China，2011，6(21)：69-70［原琦，郑曙民.LPA、HE4、CA125联检在上皮性卵巢癌诊断中的应用价值［J］.中国医疗前沿，2011，6(21)：69-70.］ ［23］Senger DR，Wirth DF，Hynes RO.Transformation-specific secreted phosophoproteins［J］ Nature，1980，286(5773)： 619-621. ［24］Fedarko NS，Jain A，Karadag A.Elevated serum bone sialoprotein and osteopontin in colon，breast，prostate，and lung cancer［J］.Clin Cancer Res，2001，7(12)：4060-4066. ［25］Wong KK，Cheng RS，Mok SC.Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system［J］.Biotechniques，2001，30(3)：670-675. ［26］Lan Z，Fu D，Yu X.Diagnostic values of osteopontin combined with CA125 for ovarian cancer： A meta-analysis［J］.Fam Cancer，2016，15(2)：221-230. ［27］Yang F，Hu ZD，Chen Y.Diagnostic value of KLK6 as an ovarian cancer biomarker： A meta-analysis［J］.Biomed Rep，2016，4(6)：681-686. ［28］Anderson GL，McIntosh M，Wu L.Assessing lead time of selected ovarian cancer biomarkers： A nested case-control study［J］.Natl Cancer Inst，2010，102(1)：26-38． ［29］Madeira K，Dondossola ER，Farias BF.Mesothelin as a biomarker for ovarian carcinoma： A meta-analysis［J］.An Acad Bras Cienc，2016，88(2)：923-932. ［30］Choudhuri S，Sharma C，Banerjee A.A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer［J］.Mol Cell Biochem，2014，386(1-2)：259-269. ［31］Chen J，Liu X，Pan YQ.Analysis of diagnostic value of YKL-40 in ovarian cancer［J］.Int J Gynecol，2016，4(6)：1048. ［32］Wang ZH，Xu CJ.Research progress of microrna in early detection of ovarian cancer［J］.Chin Med J，2015，128(24)：3363-3370. ［33］Resnick KE，Alder H，Hagan JP，et al.The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform［J］.Gynecol Oncol，2009，112(1)：55-59. ［34］An S，Song JJ.The coded functions of noncoding RNAs for gene regulation［J］.Molecules and Cells，2011，31(6)：491-496. ［35］Wilusz JE，Sunwoo H，Spector DL.Long noncoding RNAs： Functional surprises from the RNA world［J］.Genes & Development，2009，23(13)：1494. ［36］Nikpayam E，Tasharrofi B，Sarrafzadeh S.The role of long non-coding rnas in ovarian cancer［J］.Iranian Biomedical Journal，2016，21(1)：3-15.